Molecular Typing of Endometrial Cancer: A Guide to Personalized Treatment

In the outpatient clinic, a common question arises: “I’ve had surgery for endometrial cancer, why am I potentially being recommended radiation or chemotherapy?” While seemingly the same type of cancer, each tumor possesses unique characteristics. These differences often lie within the genetic makeup of the cancer cells.

The Evolution of Risk Assessment in Endometrial Cancer

Historically, doctors assessed the risk of endometrial cancer recurrence based primarily on the tumor’s stage – the extent of cancer cell invasion – and its pathological grade, indicating how aggressive the cells appeared under a microscope. This approach has been beneficial for many patients. Still, advancements in molecular medicine have revealed that even tumors with similar stages and grades can exhibit vastly different recurrence rates and treatment responses due to genetic variations.

What is Molecular Typing?

Molecular typing involves a deeper analysis of cancer, examining genetic changes within tumor cells. This allows doctors to categorize endometrial cancer into distinct subtypes. Some tumors, despite appearing high-risk under traditional pathological classification, may have a low probability of recurrence and could be spared unnecessary, potentially harmful, over-treatment. Conversely, seemingly early-stage, low-risk cases can harbor genetic changes indicating a higher recurrence risk, necessitating more aggressive follow-up treatment.

Molecular typing allows clinicians to identify “differences that cannot be seen under a microscope,” shifting treatment decisions from solely relying on appearance and extent to focusing on the tumor’s true biological characteristics. This evolution is driving a move towards personalized medicine – tailoring treatment to the individual patient and their specific tumor profile.

The Role of Genetic Mutations

Genetic mutations, often described as “spelling errors” in a gene’s code, can increase an individual’s risk of developing cancer. Several genes are linked to endometrial cancer, including:

• MLH1, MSH2, MLH3, MSH6, TGBR2, PMS1, PMS2: Mutations in these genes are associated with Hereditary non-polyposis colorectal cancer (HNPCC), similarly known as Lynch Syndrome ¹.

Other genes, such as BRCA1 and BRCA2, are more commonly associated with ovarian cancer but can also play a role in endometrial cancer risk ².

Current Guidelines and Patient Involvement

International medical guidelines now incorporate molecular subtyping into endometrial cancer risk assessment and treatment recommendations ³. Patients are encouraged to discuss with their doctors whether genetic testing is appropriate for their situation, actively participating in medical decision-making.

By gaining a deeper understanding of the “genetic character” of tumors, patients and their medical teams can collaborate to choose a treatment plan that balances effectiveness with quality of life.

Key Takeaways

• Molecular typing provides a more detailed understanding of endometrial cancer than traditional methods.
• Genetic mutations can significantly impact recurrence risk and treatment response.
• Personalized treatment approaches, guided by molecular typing, are becoming increasingly common.
• Patients should discuss genetic testing and molecular subtyping with their healthcare providers.

References

1. OncoLink. Genetic Testing for Familial Gynecologic Cancer (Endometrial and Ovarian Cancers).
2. MSKCC. Hereditary Ovarian and Uterine (Endometrial) Cancers.
3. Facing Our Risk. Endometrial Cancer Genetic Testing.